DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration
Silver Spring MD 20993

NDA 022252/Original 2

NDA APPROVAL

Bayer HealthCare Pharmaceuticals Inc.
Attention: MaryRose A. Salvacion
Associate Director, Regulatory Affairs
P.O. Box 1000
Montville, NJ 07045

Dear Ms. Salvacion:

Please refer to your New Drug Application (NDA) dated July 2, 2009, received July 6, 2009, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Natazia (estradiol valerate and estradiol valerate/dienogest) tablets.

We acknowledge receipt of your amendments dated July 14, August 11, September 23 and 30, October 13 and 15, November 3, 6, 13, and 24, and December 18 and 21, 2009; and February 1 (3), March 9, 17, and 30, April 7, 8, 9, 20, 22, 23 (2), 26 and 27, May 3 (2), 4 (2), 5, 6 (2), 25, June 15, 18, 25, July 12, 27, and 30, 2010; and June 24, September 16, October 4, December 5, 7, and 30, 2011, February 13, 23 and March 9, 2012.

The June 17, 2011, submission constituted a complete response to our August 6, 2010, action letter.

NDA 022252 provides for the use of Natazia (estradiol valerate and estradiol valerate/dienogest) tablets for two indications which, for administrative purposes, we have designated as follows:

- NDA 022252/Original 1: prevention of pregnancy.
- NDA 022252/Original 2: treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception.

The subject of this action letter is NDA 022252/Original 2. A separate action letter was issued for NDA 022252/Original 1 on May 6, 2010.

We have completed our review of this application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed agreed-upon labeling text.

We are waiving the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information. This waiver applies to all future supplements containing revised labeling unless we notify you otherwise.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the enclosed labeling (text for the package insert). Information on submitting SPL files using eLIST may be found in the guidance for industry titled "SPL Standard for Content of Labeling Technical Qs and As" at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication in pediatric patients unless this requirement is waived, deferred, or inapplicable.

We are waiving the pediatric study requirement for pre-menarcheal patients because premenarcheal patients are not at risk of becoming pregnant and the use of this product before menarche is not indicated. We note that you have fulfilled the pediatric study requirement for post-menarcheal pediatric patients by extrapolation of adult data.

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion (OPDP)
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 314.81(b)(3)(i), you must submit final promotional materials, and the package insert, at the time of initial dissemination or publication, accompanied by a Form FDA 2253. For instruction on completing the Form FDA 2253, see page 2 of the Form. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, please call Pamela Lucarelli, Regulatory Health Project Manager, at (301) 796-3961.

Sincerely,

{See appended electronic signature page}

Audrey Gassman, M.D.
Acting Deputy Director
Division of Reproductive and Urologic Products
Office of Drug Evaluation III
Center for Drug Evaluation and Research

Enclosure: Content of Labeling

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

AUDREY L GASSMAN
03/14/2012